Anxiety‐related factors associated with symptom severity in irritable bowel syndrome by Black, CJ et al.




Received:	10	February	2020  |  Revised:	10	March	2020  |  Accepted:	14	April	2020
DOI: 10.1111/nmo.13872  
O R I G I N A L  A R T I C L E
Anxiety-related factors associated with symptom severity in 
irritable bowel syndrome
Christopher J. Black1,2  |   Yan Yiannakou3 |   Lesley A. Houghton2  |   


























been associated with higher symptom severity in patients with irritable bowel syn-
drome	 (IBS);	however,	 this	 relationship	has	not	been	explored	 fully.	Moreover,	 the	
performance	 of	 the	 visceral	 sensitivity	 index	 (VSI)	 for	 measuring	 gastrointestinal	
symptom-specific	anxiety	has	not	been	examined	in	a	UK	population.	We	conducted	
a	cross-sectional	survey	to	examine	these	issues.














Conclusions and Inferences: The	 factor	 structure	 of	 the	 VSI	 requires	 further	 in-
vestigation. Our findings cast doubt on the central role of gastrointestinal symp-
tom-specific	 anxiety	 as	 a	 driver	 for	 symptom	 severity	 in	 IBS.	 Awareness	 of	 both	
gastrointestinal	and	extra-intestinal	symptoms,	however,	is	strongly	associated	with	
symptom severity.




in bowel habit.1 The prevalence in the community has previously 
been	estimated	to	be	10%,2 but in a recent study applying the Rome 
IV	criteria	in	a	UK	and	North	American	population,	the	prevalence	
was	lower,	at	around	5%.3 The condition is commoner in women and 
younger individuals.2,4	 IBS	 accounts	 for	 a	 considerable	proportion	
of referrals to gastroenterology across both secondary and tertiary 
care	settings,5	and	direct	costs	in	the	USA	have	been	estimated	at	
almost	$1	billion,	with	another	$50	million	in	indirect	costs.6
Although	 there	 are	 effective	 therapies	 available	 to	 treat	 some	
of	the	symptoms	of	IBS,7 there is no “cure” for sufferers. The chro-
nicity	of	symptoms,	which	can	fluctuate	over	time,8 may therefore 




disease,12,13	 and	 co-existent	 mood	 disorders	 are	 common.14 This 
may	be	more	 pronounced	 for	 people	with	 IBS	with	 diarrhea	 (IBS-
D)	or	 IBS	with	mixed	stool	pattern	(IBS-M).15 These patients often 
report a fear of incontinence due to loose stools and urgency16 and 
can	therefore	find	working	and	socializing	extremely	challenging.17
General	 anxiety	 is	 common	 in	 IBS	 and	 is	 associated	 with	 in-
creased severity of gastrointestinal symptoms.18 This may reflect the 
fact	that	IBS	symptoms	are	worrisome	for	some	patients,	as	with	any	
other	chronic	disease,	and	that	this	anxiety	is	therefore	secondary	
to the physical condition.19	Alternatively,	anxiety	may	influence	pain	
perception by interfering with central systems involved in process-
ing	and	modulating	noxious	visceral	afferent	signals.20




unease and fear about a wide range of situations and issues (which 
may	 include	 IBS).	 Gastrointestinal	 symptom-specific	 anxiety	 has	
been	measured	with	 a	 validated	 questionnaire,	 the	 visceral	 sensi-
tivity	 index	 (VSI).21	 Support	 for	 gastrointestinal	 symptom-specific	
anxiety	as	a	genuine	concept	 in	patients	with	 IBS	comes	 from	the	
fact	that	its	presence	seems	to	predict	a	diagnosis	of	IBS	with	good	
accuracy and that it appears to mediate the observed relationship 




group	of	Japanese	university	students,23 but its properties have not 
been	confirmed	in	a	UK	population.
It	 is	 well	 recognized	 that	 patients	 with	 IBS	 often	 complain	 of	
other	 extra-intestinal	 symptoms,24 the presence of which may be 
linked	to	mechanisms	of	central	sensitization.25	In	IBS,	somatization	
has been shown to predict both gastrointestinal symptom severity 
and	patient	consulting	behavior,26 and it is associated with most vis-
ceral sensitivity parameters.27	In	one	study,	general	anxiety	had	an	
indirect	effect	on	 IBS	symptom	severity,	via	somatization	and	cat-





been	 several	 relatively	 small	 cross-sectional	 studies	 that	 have	 ex-
amined	the	relationship	between	anxiety	and	gastrointestinal	symp-
tomatology.29-32	 In	 the	 present	 study,	 we	 first	 aimed	 to	 establish	













•	 Gastrointestinal	 symptom-specific	 anxiety,	 measured	
using	the	visceral	sensitivity	index	(VSI),	and	somatiza-
tion have both been associated with higher symptom 
severity	in	patients	with	irritable	bowel	syndrome	(IBS).
•	 This	study	in	a	large	UK	population	of	patients	with	IBS	
has	 revealed	a	 three-factor	structure	of	 the	VSI.	Most	
VSI	 items	concerned	with	overt	gastrointestinal	symp-
tom-specific	 anxiety	 loaded	 onto	 the	 two	 VSI	 factors	
that	were	not	associated	with	IBS	symptom	severity.
• Our findings cast doubt on the central role of gas-
trointestinal	 symptom-specific	 anxiety	 as	 a	 driver	
for	 symptom	 severity	 in	 IBS.	 However,	 awareness	 of	
both	 gastrointestinal	 and	 extra-intestinal	 symptoms	 is	
strongly	associated	with	IBS	symptom	severity.
     |  3 of 11BLACK et AL.
UK.	The	methodology	has	been	described	elsewhere.33	Briefly,	we	
approached	 individuals	 registered	 with	 the	 IBS	 network,	 the	 reg-
istered	charity	 for	people	 living	with	 the	condition;	TalkHealth,	an	
online social health community providing information about vari-
ous	 medical	 conditions;	 and	 ContactMe-IBS,	 a	 dedicated	 register	
allowing	individuals	with	IBS	not	receiving	specialist	care	currently	
to participate in research. Individuals registered with these three 
organizations	were	provided	with	the	opportunity	to	access	a	ques-
tionnaire	 electronically,	 between	 December	 2017	 and	 December	
2018.	 There	were	 no	 exclusion	 criteria,	 other	 than	 an	 inability	 to	
understand	written	English.	The	University	of	Leeds	research	ethics	
committee	approved	the	study	in	November	2017.
2.2 | Data collection and synthesis
2.2.1 | Demographic and gastrointestinal 
symptom data
Participants	 provided	 basic	 demographic	 data,	 including	 age,	 gen-
der,	ethnicity,	marital	status,	educational	level,	and	lifestyle	(tobacco	
and	alcohol	use).	We	also	asked	respondents	to	state	whether	they	
had seen a primary care physician or a gastroenterologist with their 
IBS	symptoms.	Lower	gastrointestinal	symptom	data	were	collected	
using	 the	 Rome	 IV	 questionnaire.34 The presence or absence of 
Rome	IV-defined	IBS	among	all	individuals	was	assigned	according	to	
the	scoring	algorithms	proposed	for	use	with	the	Rome	IV	question-
naire,1	which	are	detailed	 in	Table	S1.	 IBS	subtypes	 (IBS	with	con-










2.2.2 | Assessment of mood and somatization
General	anxiety	and	depression	scores	were	collected	using	the	hos-
pital	anxiety	and	depression	scale	(HADS).36	The	total	HADS	score	
ranges	 from	0	 to	21	 for	either	 anxiety	or	depression.	Severity	 for	
each	was	categorized	into	normal	(total	HADS-depression	or	HADS-
anxiety	 score	 0-7),	 borderline	 normal	 (8-10),	 or	 above	 threshold	
(≥11).36	 Somatization	data	were	 collected	using	 the	patient	 health	
questionnaire-12	(PHQ-12),26	derived	from	the	PHQ-15,37 which in 
turn	is	derived	from	the	validated	full	PHQ.38	The	PHQ-12	excludes	
three	 items	 from	 the	PHQ-15	 that	 refer	 to	 gastrointestinal	 symp-
toms.	The	total	PHQ-12	score	ranges	from	0	to	24	and	only	includes	
extra-intestinal	symptoms.




are	 provided	 on	 a	 six-point	 scale	 from	 “strongly	 disagree”	 (scored	
as	0)	to	“strongly	agree”	(scored	as	5).	As	mentioned	previously,	its	
developers reported a single factor structure in 100 patients with 




prior to any further analyses.
2.3 | Statistical analysis
Statistical	 analysis	 was	 performed	 using	 SPSS	 (version	 26)	 and	 R	
(version	 3.6.3).	We	 used	 Pearson's	 correlation	 coefficients	 to	 de-






test,	which	 should	be	>0.60.39	We	used	parallel	 analysis,	which	 is	
the	most	 robust	 technique,	 to	 determine	 the	 number	 of	 retained	
extracted	 factors.40 Since it is important to ensure distinct factor 
loading	to	interpret	and	name	the	factors,	we	applied	factor	rotation	
using	oblique	techniques	to	maximize	factor	loading	on	each	factor.	
We	deleted	variables	with	 loadings	<0.30	 from	 the	corresponding	
factor.39	We	 used	Cronbach's	 alpha,	 the	measure	 of	 internal	 con-
sistency	(or	coefficient	of	reliability),	to	see	how	closely	related	the	
items	were	as	a	group	for	the	VSI.	Cronbach's	alpha	of	0.70	is	a	rea-
sonable threshold for the scale to be reliable.41
We	 also	 used	 partial	 correlations	 to	 explore	 relationships	 be-
tween	 the	 key	 variables	 that	may	 affect	 the	 performance	of	 later	
regression analyses. We then carried out a series of multiple linear 
regression analyses to determine the relationship between gastro-
intestinal	 symptom-specific	 anxiety	 according	 to	 the	 VSI,	 general	
anxiety	according	to	the	HADS,	somatization	via	the	PHQ-12,	and	
gastrointestinal	 symptom	 severity	measured	 using	 the	 IBS-SSS.	 In	
every	analysis,	 the	IBS-SSS	score	was	used	as	the	dependent	vari-
able,	and	sex,	age,	marital	status,	White	Caucasian	ethnicity,	and	a	
university or postgraduate level of education were entered as co-




We carried out the analyses on the group as whole and then for the 
four	different	IBS	subtypes.	In	the	second	set	of	analyses,	we	used	
the	 total	VSI	score,	 instead	of	 the	 three	 factors,	and	repeated	the	
analyses	as	described	above.	We	estimated	both	the	unstandardized	





irrelevant variables in the model or omitting relevant variables from 
the model.
We	used	path	analysis	 to	examine	a	potential	mediating	effect	
for	 the	VSI	 on	 the	 relationship	 between	HADS-anxiety	 score	 and	
IBS-SSS	score,	as	has	been	reported	previously.21	Similarly,	we	also	
examined	 a	 potential	 mediating	 effect	 for	 the	 PHQ-12	 score	 on	
HADS-anxiety	score	and	IBS-SSS	score.
3  | RESULTS
Demographic	data	 for	 the	 cohort	 are	 summarized	 in	Table	1.	The	
mean	 age	 of	 the	 811	 included	 individuals	 was	 47.4	 years,	 697	






toms.	 The	 mean	 HADS-anxiety	 score	 was	 11.0,	 and	 442	 (54.5%)	
had	above	threshold	HADS-anxiety	scores	(≥11).	The	mean	HADS-





3.1 | Factor analysis of the VSI
The	Kaiser-Meyer-Olkin	measure	of	sampling	adequacy	of	explora-
tory	 factor	 analysis	 was	 0.94,	 above	 the	 recommended	 value	 of	
TA B L E  1  Demographics	and	psychosocial	characteristics	for	all	participants	and	for	individual	IBS	subtypes
 
Participants with 
Rome IV IBS (n = 811) IBS-C (n = 142) IBS-D (n = 311) IBS-M (n = 331) IBS-U (n = 26)
Mean	age	(SD) 47.4	(15.2) 46.1	(14.4) 47.9	(14.7) 46.6	(15.7) 57.5	(15.2)
Mean	body	mass	index	(SD) 28.4	(8.3) 25.9	(5.7) 29.6	(8.4) 28.2	(8.9) 27.8	(5.9)
Female	gender	(%) 697	(85.9) 126	(88.7) 258	(83.0) 291	(87.9) 21	(80.8)
Tobacco	user	(%) 79	(9.7) 19	(13.4) 29	(9.3) 31	(9.4) 0	(0)
Alcohol	user	(%) 442	(54.5) 72	(50.7) 184	(59.2) 175	(52.9) 11	(42.3)
Married	or	co-habiting	(%) 526	(64.9) 96	(67.6) 199	(64.0) 215	(65.0) 15	(57.7)
University	or	postgraduate	level	of	
education	(%)
315	(39.0) 56	(39.4) 133	(42.8) 117	(35.6) 9	(34.6)
White	Caucasian	ethnicity	(%) 763	(94.3) 138	(97.2) 297	(95.5) 302	(91.5) 26	(100)
Seen	a	primary	care	physician	with	IBS	(%) 778	(95.9) 133	(93.7) 300	(96.5) 318	(96.4) 26	(100)
Seen	a	gastroenterologist	with	IBS	(%) 492	(60.7) 84	(59.2) 193	(62.1) 193	(58.5) 21	(80.8)
IBS-SSS	symptom	severity	(%)
Remission 8	(1.0) 1	(0.7) 3	(1.0) 2	(0.6) 2	(7.7)
Mild 90	(11.1) 9	(6.3) 38	(12.2) 40	(12.1) 3	(11.5)
Moderate 333	(41.1) 59	(41.5) 131	(42.1) 130	(39.4) 12	(46.2)
Severe 379	(46.8) 73	(51.4) 139	(44.7) 158	(47.9) 9	(34.6)
Mean	IBS-SSS	score	(SD) 292.0	(95.8) 301.4	(86.9) 287.6	(96.3) 292.9	(96.9) 282.8	(122.8)
HADS-A	categories	(%)
Normal 202	(24.9) 32	(22.5) 89	(28.6) 73	(22.1) 8	(30.8)
Borderline 167	(20.6) 33	(23.2) 60	(19.3) 65	(19.6) 9	(34.6)
Abnormal 442	(54.5) 77	(54.2) 162	(52.1) 193	(58.3) 9	(34.6)
Mean	HADS-A	score	(SD) 11.0	(4.7) 11.3	(5.0) 10.6	(4.7) 11.3	(4.6) 9.8	(4.9)
HADS-D	categories	(%)
Normal 434	(53.5) 80	(56.3) 177	(56.9) 159	(48.0) 18	(69.2)
Borderline 191	(23.6) 23	(16.2) 64	(20.6) 101	(30.5) 2	(7.7)
Abnormal 186	(22.9) 39	(27.5) 70	(22.5) 71	(21.5) 6	(23.1)
Mean	HADS-D	score	(SD) 7.7	(4.5) 7.8	(4.8) 7.4	(4.7) 7.9	(4.1) 6.2	(4.5)
Mean	PHQ-12	score	(SD) 10.3	(4.3) 10.7	(4.6) 9.5	(4.0) 11.0	(4.4) 9.2	(4.9)
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0.60.	Using	 parallel	 analysis,	 three	 factors	were	 found	 to	 account	
for	47%	of	the	variance.	One	main	factor	(VSI	factor	one)	accounted	
for	21.1%	of	 the	variance,	with	the	second	factor	 (VSI	 factor	 two)	
accounting	for	16.5%,	and	the	third	factor	(VSI	factor	three)	10.0%.	
Table	2	 shows	 the	 items	and	 loadings	 for	each	of	 the	 factors.	VSI	
factor	one	comprised	items	1,	3,	4,	7,	and	10	of	the	VSI,	with	factor	
loadings	 from	0.55	 to	0.73,	 and	appeared	 to	be	best	described	as	
“awareness	of	 abdominal	 discomfort”.	VSI	 factor	 two	 consisted	of	
items	11,	12,	13,	and	15	with	loadings	from	0.60	to	0.91	and	included	




experiences	may	 impact	on	gastrointestinal	 symptoms.	 Items	5,	8,	
and	14	were	problematic,	since	they	showed	either	indistinct	or	low	
factor	 loading	 (<0.3),	 and	hence,	 they	were	not	 included	 in	any	of	
the	three	factors.	The	reliability	of	the	overall	VSI	and	the	three	ex-
tracted factors was above 0.70.
3.2 | Results of the regression analyses















Factor 1: worry and/or awareness of abdominal discomfort
Item 1: I worry that whenever I eat 
during	the	day,	bloating	and
0.55   
Item 3: I often worry about problems in 
my belly distension in my belly will get 
worse
0.66   
Item	4:	I	have	a	difficult	time	enjoying	
myself because I cannot get my mind 
off of discomfort in my belly
0.65   
Item	7:	No	matter	what	I	eat,	I	will	
probably feel uncomfortable
0.73   
Item 10: I am constantly aware of the 
feelings I have in my belly
0.68   
Factor 2: fear of serious illness
Item 11: I often feel discomfort in my 
belly could be a sign of serious illness
 0.69  
Item	12:	As	soon	as	I	awake,	I	worry	that	
I will have discomfort in my belly during 
the day
 0.60  
Item 13: When I feel discomfort in my 
belly,	it	frightens	me
 0.91  
Item	15:	I	constantly	think	about	what	is	
happening inside my belly













Proportion	variation 21.1% 16.5% 10.0%
Kaiser-Meyer-Olkin	measure 0.94
Cronbach's alpha 0.86 0.89 0.74
0.92	(overall)




measure and Cronbach's alpha
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TA B L E  3  Regression	models	for	all	participants	with	IBS,	and	according	to	subtype,	with	IBS-SSS	score	as	the	dependent	variable	and	the	
three-factor	VSI	included	as	an	independent	variablea
 B β t
P-




6.03 0.42 8.17 <.001 4.58	to	7.48
VSI	factor	two:	fear	of	serious	illness −0.41 −0.025 −0.54 .586 −1.87	to	1.06
VSI	factor	three:	fear	of	new	experiences −2.08 −0.09 −2.21 .27 −3.93	to	−0.23
PHQ-12 6.79 0.31 8.87 <.001 5.29	to	8.30
HADS-anxiety −4.55 −0.04 −1.15 .253 −12.34	to	3.25





4.89 0.37 3.05 .003 1.72 to 8.07
VSI	factor	two:	fear	of	serious	illness −0.31 −0.02 −0.18 .86 −3.66	to	3.04
VSI	factor	three:	fear	of	new	experiences −1.88 −0.095 −0.96 .34 −5.78	to	2.01
PHQ-12 7.90 0.42 4.15 <.001 4.39	to	11.41
HADS-anxiety −11.33 −0.11 −1.19 .24 −30.23	to	7.57





7.24 0.49 5.98 <.001 4.86	to	9.63
VSI	factor	two:	fear	of	serious	illness −0.20 −0.01 −0.18 .86 −2.43	to	2.03
VSI	factor	three:	fear	of	new	experiences −0.87 −0.037 −0.575 .565 −3.86	to	2.12
PHQ-12 5.75 0.24 4.52 <.001 3.25	to	8.25
HADS-anxiety −1.70 −0.015 −0.29 .77 −13.21	to	9.82





5.09 0.35 4.27 <.001 2.74	to	7.44
VSI	factor	two:	fear	of	serious	illness −0.96 −0.06 −0.76 .45 −3.46	to	1.53
VSI	factor	three:	fear	of	new	experiences −2.50 −0.10 −1.50 .13 −5.77	to	0.78
PHQ-12 6.73 0.30 5.40 <.001 4.28	to	9.19
HADS-anxiety −1.20 −0.01 −0.18 .86 −14.45	to	12.05





19.29 0.93 3.56 .003 7.79	to	30.80
VSI	factor	two:	fear	of	serious	illness −5.05 −0.28 −1.12 .28 −14.63	to	4.54
VSI	factor	three:	fear	of	new	experiences −7.59 −0.22 −1.43 .17 −18.89	to	3.70
PHQ-12 13.88 0.55 3.99 .001 6.51	to	21.25
HADS-anxiety −62.44 −0.42 −2.03 .06 −127.5	to	2.63
Constant −11.99  −0.09 .93 −290	to	266
 R2	=	79.2%	R2-adjusted%	=	67.5%	F	(ANOVA)	=	6.79	P-value	<.001
aControl	variables	are:	sex,	age,	marital	status,	White	Caucasian	ethnicity,	and	university	or	postgraduate	education.	
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HADS-anxiety	 score.	 The	 presence	 of	 HADS-depression	 reduced	
the	 correlation	 between	 total	 HADS-anxiety	 and	 total	 IBS-SSS	
(r = .067 P-value	=	 .57),	whereas	HADS-anxiety	appeared	 to	have	
little	effect	on	the	relationship	between	total	HADS-depression	and	
total	IBS-SSS	(r	=	.226,	P-value	<.001).	Checking	model	specification	
error	 for	omitting	variables,	 total	HADS-depression	was	 irrelevant	
to	the	model.	For	this	reason,	 in	the	main	regression	analyses,	this	
was	excluded.
The	 results	 of	 the	main	 regression	 analyses,	 for	 all	 individuals	
and	by	IBS	subtype,	are	shown	in	Table	3.	For	each	model,	the	three	
factors	of	the	VSI	were	entered	separately,	plus	HADS-anxiety	score	
and	 the	 PHQ-12	 score.	 Sociodemographic	 characteristics	 (gender,	
age,	ethnicity,	and	educational	 level)	were	 included	as	cofounders.	






tervals for the B	coefficients	were	very	wide,	which	probably	relates	
to	the	smaller	number	of	participants,	in	comparison	with	the	other	
three subtypes.
All	 the	 above	 analyses	 were	 then	 re-run	 for	 the	 group	 as	 a	





 B β t P-value 95% CI for B
All	participants	meeting	Rome	IV	criteria	for	IBS	(n	=	811)
VSI 1.88 0.29 8.16 <.001 1.43	to	2.33
HADS-anxiety −0.456 −0.02 −0.60 .55 −1.96	to	1.04
PHQ-12 6.84 0.31 8.57 <.001 5.27	to	8.40
Constant 133.330  5.01 <.001 81.09	to	186
 R2	=	25.2%	R2-adjusted%	=	24.5%	F	(ANOVA)	=	33.65	P-value	<.001
Participants	with	IBS-C	(n	=	142)
VSI 1.76 0.30 3.13 .002 0.65	to	2.89
HADS-anxiety −2.72 −0.16 −1.60 .11 −6.09	to	0.65
PHQ-12 7.39 0.39 4.15 <.001 3.87	to	10.91
Constant 149.64  2.25 .03 18.15	to	281
 R2	=	25.5%	R2-adjusted%	=	21.1%	F	(ANOVA)	=	5.70	P-value	<.001
Participants	with	IBS-D	(n	=	311)
VSI 2.79 0.425 7.74 <.001 2.08	to	3.50
HADS-anxiety −0.80 −0.039 −0.69 .49 −3.09	to	1.48
PHQ-12 6.43 0.26 4.90 <.001 3.85	to	9.01
Constant 117.17  2.93 .004 38.55	to	196
 R2	=	34.7%	R2-adjusted%	=	33.0%	F	(ANOVA)	=	20.10	P-value	<.001
Participants	with	IBS-M	(n	=	331)
VSI 1.13 0.17 3.06 .002 0.41	to	1.86
HADS-anxiety 1.03 0.049 0.81 .42 −1.47	to	3.53
PHQ-12 6.44 0.29 4.97 <.001 3.89	to	8.90
Constant 122.88  2.64 .009 31.33	to	214
 R2	=	20.0%	R2-adjusted%	=	18.0%	F	(ANOVA)	=	9.92	P-value	<.001
Participants	with	IBS-U	(n	=	26)
VSI 3.79 0.48 2.47 .024 0.57	to	7.02
PHQ-12 −2.20 −0.09 −0.37 .72 −14.76	to	
10.36
HADS-anxiety 14.68 0.58 3.41 .003 5.63	to	23.73









as an independent variablea
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gastrointestinal symptoms is unclear.45,46	It	is	reasonable	to	expect	
that patients with the highest symptom burden will have the high-
est	 levels	 of	 psychological	 problems.	However,	 there	 is	 increasing	
evidence	that	mood	problems	can	drive	IBS	symptoms,45,46 and ther-
apies	 designed	 to	 improve	 psychological	 health,	 such	 as	 cognitive	
behavioral	 therapy,7,47	or	gut-directed	hypnotherapy,48 can lead to 
symptom improvement for some patients. It is therefore important 










indicating severe symptoms. These findings are consistent with a 
clinical	population	of	IBS	sufferers.
Our	 factor	 analysis	 of	 the	 VSI	 found	 a	 three-factor	 solution,	
rather	than	a	single	factor	structure.	VSI	factor	one	included	three	
items concerned with discomfort (“I am constantly aware of the 
feelings	 I	 have	 in	my	belly,”	 “No	matter	what	 I	 eat,	 I	will	 probably	
feel	 uncomfortable,”	 and	 “I	 have	 a	 difficult	 time	 enjoying	 myself	
because	 I	 cannot	get	my	mind	off	of	discomfort	 in	my	belly”)	 and	
two items concerned with worry about gastrointestinal symptoms 
(“I	worry	 that	whenever	 I	 eat	during	 the	day,	 bloating	 and	disten-
sion in my belly will get worse” and “I often worry about problems 
in	 my	 belly”).	 The	 second	 and	 third	 factors	 included	 items	 much	
more	overtly	 related	to	anxiety	and	fear.	VSI	 factor	 two	consisted	
of items concerned with worry and fear about the potential serious 
consequences	 of	 gastrointestinal	 symptoms,	 and	 VSI	 factor	 three	
consisted of three items concerned with worries about coping with 
gastrointestinal symptoms in new environments. The three items 
which	were	not	included	in	any	of	the	three	factors	(items	5,	8,	and	
14)	were	concerned	with	worry,	 fear,	and	stress	 (“I	often	fear	that	




one	was	 independently	 associated	with	 IBS	 symptom	 severity.	As	
with	other	investigators,	we	found	that	general	anxiety	was	not	an	
independent	predictor	of	 IBS	symptom	severity.21 We did not find 
any	evidence	 that	either	 total	VSI	or	VSI	 factor	one	mediated	 the	
relationship	between	HADS-anxiety	scores	and	total	IBS-SSS,	which	
is in contrast to previous investigators.21	Our	findings	question	the	
strength	of	the	association	between	so-called	gastrointestinal-spe-




in	 the	 regression	 analyses.	 It	 appears	 that	 neither	 general	 anxiety	
nor	most	of	the	items	on	the	VSI	are	independently	associated	with	
IBS	symptom	severity.	An	awareness	of	gastrointestinal	symptoms	
















VSI	 scores,51	 the	 central	 driver	 of	 IBS	 symptom	 severity	 appears	










ment on the direction of the associations we have observed. Other 





IBS,	 gastrointestinal	 symptom-specific	 anxiety	 predicted	 future	
deterioration	in	both	symptom	severity	and	quality	of	life,	whereas	
mood	 did	 not	 appear	 to	 impact	 on	 either	 symptoms	 or	 quality	 of	
life.52	 An	 alternative	 hypothesis	 is	 that	 these	 effects	 are	 bidirec-
tional,	 as	has	been	observed	 in	 studies	examining	 the	 relationship	
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between psychological health and symptoms in patients with both 
functional and organic gastrointestinal disorders.45,46,53
Strengths	of	this	study	include	the	sample	size	and	representa-



















gastrointestinal symptoms. This may mean that we included some 








a low prevalence of organic disease.57,58	In	addition,	given	that	the	















clinical	 practice.	Moreover,	 these	patients	 are	 drawn	 from	a	 com-
munity	setting,	 rather	 than	being	 identified	using	a	hospital-based	
survey	and,	consequently,	are	likely	to	be	more	representative	of	the	
spectrum	of	 IBS	patients	as	a	whole.	 Indeed,	40%	of	patients	had	
not seen a gastroenterologist. Due to the setting in which this study 
was	conducted,	and	the	fact	that	participants	had	to	have	internet	
access,	 the	 individuals	 taking	part	may	not	be	generalizable	to	pa-
tients consulting with a gastroenterologist in secondary or tertiary 




Our	 findings	suggest	 that	 further	work	 is	 required	to	establish	
the	 factor	structure	of	 the	VSI.	We	recommend	that	 future	 inves-
tigators who use this instrument assess its factor structure prior to 
any	further	analysis,	at	least	until	a	consistent	structure	can	be	es-
tablished. The direction of the associations we have found in this 
study	between	the	PHQ-12	score,	VSI	factor	one,	and	IBS-SSS	score	










with	 IBS	 symptom	 severity	 in	 the	present	 study.	We	 suggest	 that	
interventions	 designed	 to	 treat	 gastrointestinal	 symptom-specific	
anxiety	may	be	less	helpful	in	reducing	IBS	symptom	severity	than	
previously	 supposed,	 although	 they	may	 still	 help	 with	 improving	
quality	of	life.
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